These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 30556300)

  • 21. Cost-effectiveness analysis of HLA-B5801 genotyping in the treatment of gout patients with chronic renal insufficiency in Korea.
    Park DJ; Kang JH; Lee JW; Lee KE; Wen L; Kim TJ; Park YW; Park SH; Lee SS
    Arthritis Care Res (Hoboken); 2015 Feb; 67(2):280-7. PubMed ID: 25047754
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Second-line treatment with lesinurad and allopurinol versus febuxostat for management of hyperuricemia: a cost-effectiveness analysis for Spanish patients.
    Presa M; Pérez-Ruiz F; Oyagüez I
    Clin Rheumatol; 2019 Dec; 38(12):3521-3528. PubMed ID: 31420811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial.
    Doherty M; Jenkins W; Richardson H; Sarmanova A; Abhishek A; Ashton D; Barclay C; Doherty S; Duley L; Hatton R; Rees F; Stevenson M; Zhang W
    Lancet; 2018 Oct; 392(10156):1403-1412. PubMed ID: 30343856
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost Effectiveness of Support for People Starting a New Medication for a Long-Term Condition Through Community Pharmacies: An Economic Evaluation of the New Medicine Service (NMS) Compared with Normal Practice.
    Elliott RA; Tanajewski L; Gkountouras G; Avery AJ; Barber N; Mehta R; Boyd MJ; Latif A; Chuter A; Waring J
    Pharmacoeconomics; 2017 Dec; 35(12):1237-1255. PubMed ID: 28776320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adherence and persistence to urate-lowering therapies in the Irish setting.
    McGowan B; Bennett K; Silke C; Whelan B
    Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort.
    Singh JA; Akhras KS; Shiozawa A
    Arthritis Res Ther; 2015 May; 17(1):120. PubMed ID: 25963969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system.
    Rashid N; Coburn BW; Wu YL; Cheetham TC; Curtis JR; Saag KG; Mikuls TR
    J Rheumatol; 2015 Mar; 42(3):504-12. PubMed ID: 25512479
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The rate of adherence to urate-lowering therapy and associated factors in Chinese gout patients: a cross-sectional study.
    Yin R; Cao H; Fu T; Zhang Q; Zhang L; Li L; Gu Z
    Rheumatol Int; 2017 Jul; 37(7):1187-1194. PubMed ID: 28551724
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Budget impact of adding lesinurad for second-line treatment of gout: a US health plan perspective.
    Klein RW; Kabadi S; Cinfio FN; Bly CA; Taylor DC; Szymanski KA
    J Comp Eff Res; 2018 Aug; 7(8):807-816. PubMed ID: 29792516
    [No Abstract]   [Full Text] [Related]  

  • 31. Medication adherence among gout patients initiated allopurinol: a retrospective cohort study in the Clinical Practice Research Datalink (CPRD).
    Scheepers LEJM; Burden AM; Arts ICW; Spaetgens B; Souverein P; de Vries F; Boonen A
    Rheumatology (Oxford); 2018 Sep; 57(9):1641-1650. PubMed ID: 29893941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rates of adherence and persistence with allopurinol therapy among gout patients in Israel.
    Zandman-Goddard G; Amital H; Shamrayevsky N; Raz R; Shalev V; Chodick G
    Rheumatology (Oxford); 2013 Jun; 52(6):1126-31. PubMed ID: 23392592
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States.
    Jutkowitz E; Dubreuil M; Lu N; Kuntz KM; Choi HK
    Semin Arthritis Rheum; 2017 Apr; 46(5):594-600. PubMed ID: 27916277
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness analysis of HLA-B*58: 01 genetic testing before initiation of allopurinol therapy to prevent allopurinol-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a Malaysian population.
    Chong HY; Lim YH; Prawjaeng J; Tassaneeyakul W; Mohamed Z; Chaiyakunapruk N
    Pharmacogenet Genomics; 2018 Feb; 28(2):56-67. PubMed ID: 29176400
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lifetime cost-effectiveness analysis of ticagrelor in patients with acute coronary syndromes based on the PLATO trial: a Singapore healthcare perspective.
    Chin CT; Mellstrom C; Chua TS; Matchar DB
    Singapore Med J; 2013 Mar; 54(3):169-75. PubMed ID: 23546032
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prioritizing Future Research on Allopurinol and Febuxostat for the Management of Gout: Value of Information Analysis.
    Jutkowitz E; Alarid-Escudero F; Choi HK; Kuntz KM; Jalal H
    Pharmacoeconomics; 2017 Oct; 35(10):1073-1085. PubMed ID: 28631197
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improving Adherence to Cardiovascular Therapies: An Economic Evaluation of a Randomized Pragmatic Trial.
    Smith DH; O'Keeffe-Rosetti M; Owen-Smith AA; Rand C; Tom J; Vupputuri S; Laws R; Waterbury A; Hankerson-Dyson DD; Yonehara C; Williams A; Schneider J; Dickerson JF; Vollmer WM
    Value Health; 2016; 19(2):176-84. PubMed ID: 27021751
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland.
    Hiligsmann M; McGowan B; Bennett K; Barry M; Reginster JY
    Value Health; 2012; 15(5):604-12. PubMed ID: 22867768
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.
    Hatoum H; Khanna D; Lin SJ; Akhras KS; Shiozawa A; Khanna P
    Postgrad Med; 2014 Mar; 126(2):65-75. PubMed ID: 24685969
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is HLA-B*58:01 genotyping cost effective in guiding allopurinol use in gout patients with chronic kidney disease?
    Teng GG; Tan-Koi WC; Dong D; Sung C
    Pharmacogenomics; 2020 Mar; 21(4):279-291. PubMed ID: 32180492
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.